|
|
 |
|
Viewing report
|
|
|
|
Hot Topics in Type 2 Diabetes: Physician Perceptions of Insulin - Physician survey provides insights into insulin usage and needs
Datamonitor, June 2011, Pages: 54
Introduction
Insulin prescribing practices and physician perception of unmet needs vary widely among the seven major markets. Datamonitor surveyed 199 primary care physicians and specialists across these markets on their type 2 diabetes treatment choices and prescribing behavior.
Features and benefits
- Analyze country-specific physician insulin use by therapy line and insulin class.
- Compare physician-reported trends in insulin use by class.
- Use key opinion leader insight to explain reported trends and unmet needs in the insulin market.
- Identify opportunities for insulin and non-insulin therapies to target underserved markets and physician cohorts.
Highlights
Physicians report using insulin therapy in over one-third of patients in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Insulins are predominantly used at third-line therapy and later, and as part of combination treatment regimes. Physicians expect their use of insulin to increase in the future.
Insulin use varies significantly between markets, from a low of 22% patient share in France and the UK, where oral drugs are preferred, to 43% of patients at using insulin at the current time, in Germany. Markets with higher use also have earlier initiation of insulin.
Basal insulins and prandial insulin, particularly the analogs, have come to dominate insulin therapy in recent times. Lantus dominates basal insulin use, on the basis of its concentration profile in the body. However, little difference is perceived between the insulin options, and individual patient response is a major factor.
Your key questions answered
- Delve into primary data from 199 seven major market physicians on present insulin usage and trends.
- Use key opinion leader insight to elucidate differences in prescribing practices among the major markets.
- Identify unmet needs in insulin therapy and opportunities in the type 2 diabetes treatment algorithm.
|
|
|
|
